Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor
Colorectal Cancer - Onvansertib, a Novel Oral PLK1 Inhibitor

Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor

Background On average, KRAS is mutated in approximately 50% of patients with colorectal cancer. Chemotherapy in combination with targeted drugs is standard of care option for patients with metastatic colorectal…

Continue Reading Colorectal cancer – Onvansertib, a Novel Oral PLK1 Inhibitor